TapewireFind a company

person · Reporting owner

Fardis Maria

Disclosed activity across 3 companies

Tapewire entity
26160
SEC CIK
0001559231

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CRISPR Therapeutics AGCRSP · Entity 3852DirectorJune 05, 2026June 09, 2026
IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090Director · President and CEOJanuary 04, 2021January 06, 2021
Obsidian Therapeutics, Inc.OBX · Entity 4898DirectorAugust 03, 2026August 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05Direct13,000 Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

IOVANCE BIOTHERAPEUTICS, INC.

Report date January 04, 2021 · Filed January 06, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.26 · Expires 2031-01-04Direct250,000 Reported balance After 2021-01-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-01-04 · Grant · Acquired 250,000 · Balance 250,000

F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Obsidian Therapeutics, Inc.

Report date August 03, 2026 · Filed August 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02Direct37,653 Reported balance After 2026-08-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653

F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 03, 2026 Filed Aug 5, 2026 20:05 UTC Obsidian Therapeutics, Inc. OBX · Entity 4898 GrantStock Option (Right to Buy) · Derivative 37,653 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0001193125-26-335045 · ownership.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,653

Underlying: Common Stock · 37,653 shares

Expires 2036-08-02

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:43 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 13,000 $0.00 Strike: $51.84 $0.00
Disclosure

SEC source: 0001193125-26-264290 · ownership.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Shares · 13,000 shares

Expires 2036-06-05

F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:30 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 13,000 $0.00 Strike: $38.57 $0.00
Disclosure

SEC source: 0000950170-25-083268 · ownership.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Shares · 13,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders.

Read SEC document
May 30, 2024 Filed May 31, 2024 20:15 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 13,000 $0.00 Strike: $54.06 $0.00
Disclosure

SEC source: 0000950170-24-067326 · ownership.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Shares · 13,000 shares

Expires 2034-05-30

F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders.

Read SEC document
June 08, 2023 Filed Jun 9, 2023 21:33 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 13,000 $0.00 Strike: $62.59 $0.00
Disclosure

SEC source: 0001209191-23-035974 · doc4.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Shares · 13,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders.

Read SEC document
June 09, 2022 Filed Jun 10, 2022 21:37 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 24,000 $0.00 Strike: $71.70 $0.00
Disclosure

SEC source: 0001209191-22-036037 · doc4.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Shares · 24,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 24,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.

Read SEC document
January 04, 2021 Filed Jan 6, 2021 22:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 GrantStock Option (right to buy) · Derivative 250,000 $0.00 Strike: $46.26 $0.00
Disclosure

SEC source: 0001104659-21-001577 · tm211898-3_4seq1.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2031-01-04

F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Read SEC document
June 01, 2020 Filed Jun 2, 2020 23:19 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,894 $33.12 $62,729.28
Disclosure

SEC source: 0001104659-20-069097 · tm2021603d1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,786

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

Read SEC document
May 01, 2020 Filed May 5, 2020 01:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,894 $32.00 $60,608.00
Disclosure

SEC source: 0001104659-20-056429 · tm2018523-1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,680

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested RSUs.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 20:30 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,494 $27.94 $41,742.36
Disclosure

SEC source: 0001104659-20-043125 · tm2014835d1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,574

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested RSUs.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 22:00 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $35.99 $47,542.79
Disclosure

SEC source: 0001104659-20-029218 · tm2011589d1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,068

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested RSUs.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 21:31 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,302 $22.54 $29,347.08
Disclosure

SEC source: 0001104659-20-011256 · tm206837-1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,389

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested RSUs.

Read SEC document
January 03, 2020 Filed Jan 8, 2020 02:00 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 GrantStock Option (right to buy) · Derivative 500,000 $0.00 Strike: $25.54 $0.00
Disclosure

SEC source: 0001104659-20-002086 · tm201473d1_4.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common stock · 500,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 500,000 shares shall vest on the one-year anniversary of January 3, 2020; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of January 3, 2020.

Read SEC document
January 02, 2020 Filed Jan 7, 2020 00:00 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,562 $26.68 $41,674.16
Disclosure

SEC source: 0001104659-20-001682 · tm201275d1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306,691

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested RSUs.

Read SEC document
December 02, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,894 $22.66 $42,918.04
Disclosure

SEC source: 0001104659-19-070008 · tm1924459d2_4.xml · nonDerivative · entry 2

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 308,253

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
November 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,894 $21.97 $41,611.18
Disclosure

SEC source: 0001104659-19-070008 · tm1924459d2_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,147

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
October 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,894 $18.21 $34,489.74
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 30

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,041

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
September 03, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,610 $20.27 $32,634.70
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 29

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,935

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
August 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $25.17 $33,249.57
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 28

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,545

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
July 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $24.62 $32,523.02
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 27

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,866

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
June 03, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $18.04 $23,830.84
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 26

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,187

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
May 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $11.14 $14,715.94
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 25

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 319,508

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
April 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $9.78 $12,919.38
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 24

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,829

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
March 04, 2019 Filed Mar 6, 2019 22:00 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 GrantStock Option (right to buy) · Derivative 400,000 $0.00 Strike: $11.26 $0.00
Disclosure

SEC source: 0001144204-19-012581 · tv515609_4.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common stock · 400,000 shares

Expires 2019-03-04

F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 400,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019.

Read SEC document
March 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,298 $10.77 $13,979.46
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 23

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,150

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
February 01, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,562 $9.26 $14,464.12
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 22

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 323,448

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
January 02, 2019 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,562 $9.45 $14,760.90
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 21

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,010

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
December 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $10.44 $13,791.24
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 20

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,572

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
November 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $9.62 $12,708.02
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 19

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,893

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
October 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $11.12 $14,689.52
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 18

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,214

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
September 04, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $17.10 $22,589.10
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 17

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,535

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
August 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $13.70 $18,097.70
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 16

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,856

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
July 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $12.80 $16,908.80
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 15

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,177

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
June 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $14.55 $19,220.55
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 14

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 334,498

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
May 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $14.60 $19,286.60
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 13

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,819

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
April 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $16.90 $22,324.90
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 12

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,140

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
March 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,321 $18.15 $23,976.15
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 11

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,461

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
February 09, 2018 Filed Feb 13, 2018 01:18 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 GrantStock Option (right to buy) · Derivative 500,000 $0.00 Strike: $16.80 $0.00
Disclosure

SEC source: 0001250853-18-000038 · primary_doc.xml · derivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2028-02-08

F1 · derivative.exercise_date: Provided the Reporting Person is employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of 166,672 shares shall vest on February 9, 2019; and (ii) the remaining stock options shall vest as to 41,666 shares in eight quarterly installments over the two years following February 9, 2019.

Read SEC document
February 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,525 $16.50 $25,162.50
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 10

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,782

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
January 01, 2018 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,562 $8.00 $12,496.00
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 9

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,307

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
December 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,994 $8.80 $17,547.20
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 8

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,869

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
November 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,994 $7.15 $14,257.10
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 7

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,863

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
October 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,993 $7.75 $15,445.75
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 6

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,857

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
September 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,994 $6.00 $11,964.00
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 5

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,850

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
August 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,993 $5.70 $11,360.10
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 4

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,844

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
July 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 1,994 $7.35 $14,655.90
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 3

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,837

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
June 01, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 143,496 $5.45 $782,053.20
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 2

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,831

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document
April 03, 2017 Filed Dec 5, 2019 02:01 UTC IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 Tax withholdingCommon Stock 51,673 $7.15 $369,461.95
Disclosure

SEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 1

Fardis Maria · CIK 0001559231 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 498,327

F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs").

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.